What Happened?
Shares of healthcare tech company GoodRx (NASDAQ: GDRX) jumped 3.6% in the afternoon session after the company announced it now offers access to the new higher-dose Wegovy® HD (semaglutide) injection for self-pay patients at a price of $399 per month.
This move came amid a growing demand for GLP-1 treatments, a class of drugs that includes Wegovy. GoodRx's initiative simplified access to the popular medication by providing clear pricing that scaled with quantity. A two-month supply was made available for $798, and a three-month supply for $1,197. The effort was seen as a way to provide consumers with flexibility and predictable costs, tapping into the significant self-pay market for these sought-after treatments.
After the initial pop the shares cooled down to $2.33, up 4% from previous close.
Is now the time to buy GoodRx? Access our full analysis report here, it’s free.
What Is The Market Telling Us
GoodRx’s shares are extremely volatile and have had 37 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 8 months ago when the stock gained 40.2% on the news that the company announced a collaboration with pharmaceutical giant Novo Nordisk to offer the popular medications Ozempic and Wegovy for $499 per month to eligible self-paying customers.
This landmark collaboration makes the popular GLP-1 medications—used for type 2 diabetes (Ozempic) and weight loss (Wegovy)—available at a significantly lower cost to those who lack adequate insurance coverage. According to the announcement, this marks the first time Ozempic has been offered at this self-pay price point. The offer is effective immediately and available through the GoodRx platform at over 70,000 retail pharmacies nationwide. Investors reacted positively, viewing the strategic partnership as a pivotal move that could substantially expand GoodRx's market reach and user base by capitalizing on the high-demand therapeutic category.
GoodRx is down 15.5% since the beginning of the year, and at $2.33 per share, it is trading 54.6% below its 52-week high of $5.12 from August 2025. Investors who bought $1,000 worth of GoodRx’s shares 5 years ago would now be looking at only $60.77.
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.
